Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 13, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$4.94B
sum of reported positions
Reported positions
117
Changes vs prior quarter
89
27 new · 10 exited
Filings on record
8
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024
Across 131 measured positions in 7 quarters, the typical new or larger position finished −3.0 pts against the S&P 500 and 43% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 9.58M | $527M | 10.7% | |
| 2.94M | $337M | 6.8% | |
| 11.4M | $209M | 4.2% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $3.61B | $4.94B |
| Positions | 100 | 117 |
| Biggest line | — | Scholar Rock Holding 11% |
| 1.66M |
| $204M |
| 4.1% |
| 6.18M | $193M | 3.9% |
| 900K | $169M | 3.4% |
| 5.6M | $166M | 3.4% |
| 1.72M | $140M | 2.8% |
| 465K | $133M | 2.7% |
| 3.18M | $129M | 2.6% |
| 1.14M | $126M | 2.6% |
| 44.3M | $106M | 2.2% |
| 1.77M | $90.1M | 1.8% |
| 969K | $86M | 1.7% |
| 2.99M | $81.9M | 1.7% |
| 1.32M | $79.6M | 1.6% |
| 7.69M | $76.8M | 1.6% |
| 576K | $76.8M | 1.6% |
| 2.09M | $76.6M | 1.6% |
| 2.42M | $74.6M | 1.5% |
| 1.86M | $72M | 1.5% |
| 3.65M | $68.3M | 1.4% |
| 9.85M | $67.1M | 1.4% |
| 1.42M | $66.8M | 1.4% |
| 2M | $65.3M | 1.3% |
Parabilis Medicines (PBLS)
2.99M shares
Abivax (ABVX)
576K shares
Hemab Therapeutics Holdings (COAG)
2.09M shares
Relay Therapeutics (RLAY)
3.65M shares
Kailera Therapeutics (KLRA)
2.21M shares
Capital One (COF)
172K shares
Oruka Therapeutics (ORKA)
250K shares
Seaport Therapeutics (SPTX)
1.1M shares
Tyra Biosciences (TYRA)
725K shares
Adagene (ADAG)
2.67M shares
Engene Therapeutics (ENGN)
6.26M shares
Microsoft (MSFT) · CALL
24K shares
Oculis Holding (OCS)
625K shares
Design Therapeutics (DSGN)
523K shares
Apple (AAPL) · CALL
23K shares
Eloxx Pharmaceuticals (ELOX)
400K shares
Alibaba Group Holding (BABA)
50K shares
Ouster (OUST)
68K shares
Palisade Bio (PALI)
2M shares
Odyssey Therapeutics (ODTX)
200K shares
Zoetis (ZTS)
35K shares
Netflix (NFLX)
25K shares
Quantinuum (QNT)
20K shares
Entera Bio (ENTX)
736K shares
Lumentum (LITE)
1,055 shares
